Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803083 | 0.90 | CCR3 (0.58) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL3307904 | 0.89 | CCR3 (0.61) | CCR3ACHEALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL8907111 | 0.87 | CCR3 (0.63) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL6749556 | 0.86 | CCR3 (0.58) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL20314493 | 0.85 | HRH3 (0.49) | CCR3ACHEALDH1A1CXCR4 | |
| SCHEMBL15140944 | 0.84 | CCR3 (0.73) | CCR3ACHEALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL13003723 | 0.84 | CCR3 (0.55) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL803087 | 0.83 | ACHE (0.49) | CCR3ACHEALDH1A1SIGMAR1 | |
| SCHEMBL69200 | 0.83 | CCR3 (0.67) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL6749208 | 0.82 | CCR3 (0.54) | CCR3ACHEALDH1A1CXCR4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2019-05-02 | — | — | US | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-8962642-B2 | 5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-24 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-8247421-B2 | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100189773-A1 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-07-29 | — | — | US | disclosed |
| US-20100168114-A1 | INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2010-07-01 | — | — | US | disclosed |
| US-20100168114-A1 | INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2010-07-01 | — | — | US | disclosed |
| US-20080312091-A1 | INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2008-12-18 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | CCR3 845/4885ACHE 1731/4885ALDH1A1 1984/4885 |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | CCR3 845/4885ACHE 1731/4885ALDH1A1 1984/4885 |
| US-20100168114-A1 | INVERTEBRATE ACETYLCHOLINESTERASE INHIBITORS | ACHE, BCHE, CHAT | CCR3 4292/4885ACHE 1/4885ALDH1A1 596/4885 |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | CCR3 1016/4885ACHE 3961/4885ALDH1A1 1629/4885 |
| US-20100189773-A1 | 5-CYANO-4- (PYRROLO [2,3] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP3K20 | CCR3 2340/4885ACHE 3014/4885ALDH1A1 4040/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | CCR3 857/4885ACHE 1686/4885ALDH1A1 2154/4885 |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | CCR3 1016/4885ACHE 3961/4885ALDH1A1 1629/4885 |
| US-10752622-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | CCR3 987/4885ACHE 3907/4885ALDH1A1 1844/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | CCR3 3327/4885ACHE 2298/4885ALDH1A1 617/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | CCR3 4152/4885ACHE 3243/4885ALDH1A1 2036/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | CCR3 987/4885ACHE 3907/4885ALDH1A1 1844/4885 |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | CCR3 1016/4885ACHE 3961/4885ALDH1A1 1629/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | CCR3 517/4885ACHE 746/4885ALDH1A1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.